Screener
Opko Health OPK R&D
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Opko Health in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Opko Health’s 10-Q, filed July 27, 2026.
- Filed
- Jul 27, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-318090
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| Cost of service revenue | 58,462 | 82,383 | 114,604 | 166,901 |
| Cost of product revenue | 25,101 | 25,022 | 47,399 | 47,836 |
| Selling, general and administrative | 52,924 | 59,597 | 101,531 | 118,683 |
| Research and development | 33,166 | 30,342 | 62,365 | 61,183 |
| Amortization of intangible assets | 18,969 | 19,444 | 37,935 | 39,304 |
| Gain on sale of assets | (18,070) | — | (18,070) | — |
| Total costs and expenses | 170,552 | 216,788 | 345,764 | 433,907 |
| Operating loss | (6,972) | (59,981) | (57,987) | (127,148) |
Item 1. Financial Statements
FAQ
- What is Opko Health's R&D?
- Opko Health (OPK) reported R&D of $33.17M in Q2 2026.
- How has Opko Health's R&D changed year-over-year?
- Opko Health's R&D increased by 9.3% year-over-year, from $30.34M to $33.17M.
- What is the long-term trend for Opko Health's R&D?
- Over 3 years (2021 to 2025), Opko Health's R&D has grown at a 17.3% compound annual growth rate (CAGR), from $76.85M to $124.03M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Opko Health's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude